Late-Stage Breast Cancer Diagnosis on Rise in U.S.
Medpage Today on MSN5h
HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast CancerA HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...
Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...
A 40-year-old woman who was denied a life-extending cancer drug because it is not available in Wales has died.Rachel Davies, ...
Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...
News Medical on MSN6h
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancerAlliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...
This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...
Breast cancer caregiving was the last thing on John K. Conner’s mind back in 1998. He and his wife, Anita T. Conner, were in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback